Index BooK
Cremas, Ungüentos, Lociones, Gel
1- Aclovate
2- Valisone
3- Diprolene
4- Temovate
5- Desowen
6- Synalar
7- Lidex
8- Ultravate
9- Cortisol
10- Elocon
11- Mycolog II
12- Mytrex
13- Accutane
14- Retin-A
15- Denavir
16- Aldara
17- Lotrisone
18- Ery pads
19- Metro Gel
20- Benzac
21- Neosporin
22- Cleocin
23- Zovirax
24- Elidel
25- Xylocaine
26- Proctofoam
27- Prax
28- Lidocaine
29- Caladryl
30- Benadryl
31- Dermoplast
32- Anusol
33- Anucort HC
34- Proctosol HC
35- Westcort
36- Bactrobam
37- Cutivate
38- Clobex
39- Locoid
40- Dermoplast
41- Bactine
42- Silvadene
FDA Pregnancy Categories
The FDA has established five categories to indicate the potential of a drug to cause birth defects if used during pregnancy. The categories are determined by the reliability of documentation and the risk to benefit ratio. They do not take into account any risks from pharmaceutical agents or their metabolites in breast milk. The categories are:
Category A
Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
Category B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Category X
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
Category N
FDA has not classified the drug.
